• PDF / 168,992 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 14 Downloads / 131 Views

DOWNLOAD

REPORT

---

1 S

Death: case report In a retrospective, single-institution analysis of 46 patients (aged 34–81 years) with metastatic renal cell carcinoma (mRCC), who started receiving first-line treatment between March 2018 and April 2019 at a clinic in the USA, a patient [age and sex not stated] was described, who died due to unspecified immune-related adverse events (irAEs) during treatment with ipilimumab and nivolumab for mRCC [routes, dosages and durations of treatments to reaction onset not stated]. Desai K, et al. Retrospective analysis of immune-related adverse events (irAE) in metastatic renal cell carcinoma (mRCC) patients treated with first-line ipilimumab and nivolumab (I+N). Journal of Clinical Oncology 38 (Suppl.): e17094, No. 15, 2020. Available from: URL: http://doi.org/10.1200/JCO.2020.38.15_suppl.e17094 803503111 [abstract]

0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 26 Sep 2020 No. 1823